Source: Annual Congress 2001 - Mesothelioma, malignant pleural effusions and rare thoracic tumours
Disease area: Respiratory infections, Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
M. Ferdoutsis, G. Meletis, G. Patsourakis, N. Bachlitzanakis, E. Vakouti, M. Christodoulou, G. Pitsidianakis, G. Gavriilidis, D. Bouros (Heraklion, Greece). Prognostic indexes for the efficacy of intrapleural instillation of bleomycin, alpha2-interferon and gamma-interferon in the control of malignant pleural effusions. Eur Respir J 2001; 16: Suppl. 31, 2710

Member's Comments

No comment yet.

Related content which might interest you: Efficacious pleurodesis with OK-432 and doxorubicin against malignant pleural effusions Source: Eur Respir J 2004; 24: 263-266 Year: 2004 Intrapleural perfusion hyperthermo-chemotherapy for malignant pleural effusion Source: Annual Congress 2009 - Preoperative functional assessment and surgery for malignant diseases Year: 2009 Malignant pleural effusion: treatment of the fluid and intrapleural therapy Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases Year: 2020 Management of malignant pleural effusion in recurrent SCLC by intrapleural gene therapy Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003 Talc slurry vs bleomycin in treatment of malignant pleural effusions Source: Eur Respir J 2005; 26: Suppl. 49, 448s Year: 2005 Pleurodesis of malignant pleural effusion with OK432 Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003 Comparison between treatment with IL2, and IL2 in combination with chemotherapy in malignant pleural mesothelioma Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009 Efficacy and safety of talc pleurodesis in patients with malignant pleural effusions Source: Eur Respir J 2006; 28: Suppl. 50, 754s Year: 2006 Comparison in effectiveness and proinflammatory mediators between talc, doxycycline and tetracycline for pleurodesis in malignant pleural effusions (MPE) Source: Annual Congress 2006 - New developments in diagnostic and therapeutic bronchoscopy and thoracoscopy Year: 2006 Efficacy of talc pleurodesis in patients with malignant pleural effusions Source: Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions Year: 2011 Efficacy of rapid pleurodesis in malignat pleural effusions Source: Annual Congress 2010 - Clinical diagnosis and management of malignant pleural effusions Year: 2010 Intrapleural fibrinolysis modulation in malignant pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 517s Year: 2001 Prognostic significance of pleural tumour burden in patients with malignant pleural effusions Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement? Year: 2010 LL-37 is produced intrapleurally in infectious pleural effusion Source: Annual Congress 2012 - Prognostic indices in respiratory infections Year: 2012 Effecs of systemic inflammation markers for determining success of talc pleurodeisis on patients with malignant pleural effusion Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003 Low dose vs high dose talc pleurodesis for malignant pleural effusion Source: Annual Congress 2011 - From outside to inside: access to the pleura Year: 2011 Efficacy and safety of autologous blood pleurodesis versus talc pleurodesis in patients with malignant pleural effusions: Preliminary results Source: Annual Congress 2012 - Biology and treatment of malignant pleural effusions Year: 2012 Talc mediates angiostasis in malignant pleural effusions via endostatin induction Source: Eur Respir J 2007; 29: 761-769 Year: 2007 The diagnostic value of gama interferon level of pleural effusions in tubercuolus pleurisy Source: Eur Respir J 2006; 28: Suppl. 50, 140s Year: 2006 Pleurodesis for malignant pleural effusions: A comparison of bleomycin or tranexamic acid alone versus a combination of both Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013